Bull
$0.61
情境價格
$0.840
-0.058 (-6.92%)收盤時
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

HOOKIPA Pharma Sells Immuno-Oncology Assets to NeoTrail Therapeutics

HOOKIPA Pharma Sells Immuno-Oncology Assets to NeoTrail Therapeutics

HOOKIPA Pharma Sells Immuno-Oncology Assets to NeoTrail

HOOKIPA Pharma Finalizes Sale of HBV and HIV Assets to Gilead

HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics based on its arenavirus platform. The Company’s product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. Its two primary programs include HB-700 and Eseba-vec. HB-700 is a multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Eseba-vec is an investigational immunotherapeutic agent in clinical development for the treatment of HPV16+ head and neck cancers. The Company has partnered with Gilead Sciences, Inc. to develop therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。